YHR140W Antibody

What is YHR140W and which organisms express this protein?

YHR140W is a UPF0641 membrane protein found in Saccharomyces cerevisiae (Baker's yeast), specifically in strain 204508/S288c. This protein is encoded by the YHR140W gene and is characterized as a hypothetical membrane protein . The protein's function involves membrane-associated processes in yeast cells, though many aspects of its specific biological role remain under investigation in current research.

What types of YHR140W antibodies are commercially available?

Currently, polyclonal antibodies against YHR140W are available for research purposes. These are typically rabbit-derived polyclonal antibodies that have undergone antigen-affinity purification to ensure specificity. The available antibodies are of IgG isotype and have been validated for applications such as ELISA and Western Blot analyses . Researchers should note that validation data for additional applications may vary between suppliers and should be carefully assessed.

What are the recommended applications for YHR140W antibodies?

YHR140W antibodies have been validated primarily for ELISA (Enzyme-Linked Immunosorbent Assay) and Western Blot applications to ensure proper identification of the antigen . These techniques are particularly useful for detecting the presence of YHR140W protein in yeast samples and characterizing its expression levels under different experimental conditions. Additional applications may require further validation by individual researchers.

How should researchers evaluate the quality of YHR140W antibodies?

Researchers should assess YHR140W antibodies using comprehensive validation approaches similar to those employed by initiatives like YCharOS, which characterizes antibodies through multiple techniques including knockout validation . When evaluating a YHR140W antibody, researchers should:

• Verify specificity using positive controls (S. cerevisiae expressing YHR140W)

• Include negative controls (YHR140W knockout strains if available)

• Test cross-reactivity with related proteins

• Confirm reproducibility across different batches

• Validate for specific applications (Western blot, ELISA, etc.)

How do polyclonal and monoclonal approaches differ for YHR140W antibody production?

The current commercially available YHR140W antibodies are polyclonal, produced in rabbits against specific YHR140W epitopes . For researchers considering custom antibody development:

Polyclonal YHR140W antibodies:

• Recognize multiple epitopes across the YHR140W protein

• Typically provide stronger signals due to multiple binding sites

• Show batch-to-batch variation in epitope recognition

• Production is generally faster and less technically demanding

Potential monoclonal YHR140W antibodies:

• Would target a single, specific epitope on YHR140W

• Would offer higher reproducibility between batches

• Development would require hybridoma technology involving mouse immunization, splenic cell harvesting, and fusion with immortalized cell lines

• Production requires more sophisticated techniques but provides more consistent results

The decision between polyclonal and monoclonal approaches should be based on specific research needs, with monoclonal antibodies being preferred for longitudinal studies requiring high consistency.

What considerations should guide epitope selection for YHR140W antibody development?

When designing custom YHR140W antibodies, researchers should consider the following factors for epitope selection:

• Membrane topology analysis: As YHR140W is a membrane protein, researchers should predict transmembrane domains and select epitopes from accessible regions

• Sequence conservation: Analyze conservation within S. cerevisiae strains if strain-cross-reactivity is desired

• Post-translational modifications: Avoid regions likely to be glycosylated or otherwise modified

• Structural predictions: Use computational modeling to identify surface-exposed regions

• Unique sequences: Select epitopes that distinguish YHR140W from related proteins to minimize cross-reactivity

The most effective epitopes will typically be 10-20 amino acids in length, have moderate hydrophilicity, and be located in accessible regions of the protein's native conformation.

How can researchers address contradictory results when using YHR140W antibodies?

When faced with contradictory results using YHR140W antibodies, researchers should systematically troubleshoot using the following approach:

• Validate antibody performance: Re-test antibody specificity using positive and negative controls

• Compare different detection methods: If Western blot results contradict ELISA findings, consider protein conformational differences between methods

• Evaluate protein expression conditions: YHR140W expression may vary with growth conditions and stress factors

• Check for post-translational modifications: These may affect epitope recognition

• Consider protein-protein interactions: Binding partners may mask antibody binding sites

Collaborative initiatives like YCharOS have demonstrated that comprehensive characterization of antibodies can reveal significant variability in performance, which may explain contradictory results between laboratories .

What is the optimal protocol for Western blot detection of YHR140W?

Based on standard protocols for membrane proteins and available information on YHR140W , the following Western blot protocol is recommended:

Sample preparation:

• Harvest yeast cells during log-phase growth

• Lyse cells using glass beads or enzymatic methods in the presence of protease inhibitors

• Isolate membrane fractions through differential centrifugation

• Solubilize membrane proteins using appropriate detergents (e.g., 1% Triton X-100 or 0.5% SDS)

Western blot procedure:

• Separate proteins on 10-12% SDS-PAGE gels

• Transfer to PVDF membrane (recommended over nitrocellulose for membrane proteins)

• Block with 5% BSA in TBST (preferred over milk for membrane proteins)

• Incubate with YHR140W antibody at 1:1000 dilution

• Wash extensively with TBST

• Incubate with appropriate secondary antibody (anti-rabbit IgG-HRP)

• Develop using ECL substrates

• Include positive controls (wild-type yeast lysate) and negative controls (YHR140W deletion strain if available)

How can researchers optimize immunoprecipitation using YHR140W antibodies?

While the current data specifically lists ELISA and Western blot as validated applications , researchers may adapt immunoprecipitation protocols for YHR140W using the following optimization strategies:

Immunoprecipitation protocol optimization:

• Lysis buffer selection: Use buffers containing 1% digitonin or 0.5% NP-40 to maintain membrane protein conformations

• Antibody coupling: Pre-couple YHR140W antibody to protein A/G beads to minimize background

• Pre-clearing step: Include pre-clearing with protein A/G beads to reduce non-specific binding

• Detergent screening: Test multiple detergents (Triton X-100, CHAPS, DDM) to optimize YHR140W solubilization while maintaining epitope recognition

• Cross-linking consideration: For transient interactions, consider using reversible cross-linking reagents

Expected challenges:

• Membrane protein solubilization while maintaining native conformation

• Distinguishing true interactors from non-specific membrane protein associations

• Potentially low expression levels of YHR140W

What controls are essential when using YHR140W antibodies in research?

Based on findings from antibody characterization initiatives , researchers should implement the following controls when working with YHR140W antibodies:

Essential controls table:

These controls are particularly important given that YCharOS data demonstrates that up to 50% of commercially available antibodies may exhibit performance issues in specific applications .

Why might Western blot detection of YHR140W show multiple bands?

Multiple bands in Western blots using YHR140W antibodies may result from several factors:

• Post-translational modifications: Different glycosylation states or other modifications of YHR140W

• Proteolytic processing: Incomplete protease inhibition during sample preparation

• Protein aggregation: Incomplete denaturation of this membrane protein

• Non-specific binding: Particularly if the antibody has cross-reactivity with related proteins

• Oligomerization: Formation of dimers or higher-order structures

To address this issue, researchers should:

• Include fresh protease inhibitors in lysis buffers

• Optimize denaturation conditions (temperature, reducing agents)

• Perform peptide competition assays to identify specific bands

• Consider using gradient gels for better resolution

How can researchers address weak or absent signals when using YHR140W antibodies?

When encountering weak or absent signals:

• Protein expression verification: Confirm YHR140W expression under your experimental conditions using RT-PCR

• Sample preparation optimization:

  • For membrane proteins like YHR140W, standard lysis buffers may inefficiently extract the protein

  • Test specialized membrane protein extraction buffers containing appropriate detergents

• Signal enhancement strategies:

  • Increase antibody concentration (up to 1:500 dilution)

  • Extend primary antibody incubation (overnight at 4°C)

  • Use signal enhancement systems (biotin-streptavidin amplification)

• Transfer optimization: For membrane proteins, adjust transfer conditions (longer times, lower voltage)

• Detection system sensitivity: Switch to more sensitive detection methods (fluorescent secondaries or high-sensitivity chemiluminescent substrates)

What strategies help overcome non-specific binding with YHR140W antibodies?

Non-specific binding is a common challenge with polyclonal antibodies like those against YHR140W . Researchers should implement these strategies:

• Blocking optimization:

  • Test different blocking agents (BSA, casein, commercial blockers)

  • Increase blocking time (2-3 hours at room temperature)

• Antibody dilution optimization:

  • Perform titration experiments to find optimal concentration

  • Prepare antibody dilutions in blocking buffer containing 0.1-0.3% Tween-20

• Wash stringency increase:

  • Extend wash times (5 x 10 minutes)

  • Include up to 0.1% SDS in wash buffers for Western blots

• Pre-absorption strategy:

  • Pre-absorb antibody with lysates from species/tissues not expressing YHR140W

• Secondary antibody consideration:

  • Use highly cross-adsorbed secondary antibodies to reduce non-specific binding

How can YHR140W antibodies be applied to study protein-protein interactions?

YHR140W antibodies can facilitate the study of protein-protein interactions through:

• Co-immunoprecipitation (Co-IP):

  • Use YHR140W antibodies to pull down the protein and associated complexes

  • Analyze co-precipitated proteins by mass spectrometry or Western blotting

  • Consider membrane-specific Co-IP protocols to maintain interaction integrity

• Proximity labeling:

  • Create fusion constructs with BioID or APEX2 proximity labeling enzymes

  • Use YHR140W antibodies to confirm expression and localization of fusion proteins

  • Identify proteins in proximity to YHR140W through biotin labeling and pulldown

• Immunofluorescence co-localization:

  • While not explicitly validated , YHR140W antibodies may be optimized for immunofluorescence

  • Combine with antibodies against potential interacting proteins

  • Quantify co-localization using appropriate statistical methods

What considerations apply when using YHR140W antibodies for studying protein localization?

When optimizing immunofluorescence protocols for YHR140W localization studies:

• Fixation method selection:

  • For membrane proteins, mild fixation (0.5-2% formaldehyde) often preserves epitopes better than harsh fixation

  • Test both formaldehyde and methanol fixation methods

• Permeabilization optimization:

  • Membrane proteins require careful permeabilization

  • Test detergents at lower concentrations (0.1% Triton X-100, 0.05% saponin)

  • Consider digitonin for selective plasma membrane permeabilization

• Blocking and antibody incubation:

  • Use fish gelatin or BSA rather than serum for blocking

  • Extend primary antibody incubation (overnight at 4°C)

  • Include low concentrations of detergent (0.05% Tween-20) in antibody solutions

• Controls for specificity:

  • Include YHR140W deletion strains as negative controls

  • Use known markers of subcellular compartments for co-localization

  • Perform peptide competition assays to verify signal specificity

How can researchers apply YHR140W antibodies to study protein expression under different conditions?

YHR140W antibodies can be valuable tools for studying expression patterns under various conditions:

• Expression profiling across growth phases:

  • Collect yeast samples at different growth phases (lag, log, stationary)

  • Analyze YHR140W expression by Western blot or ELISA

  • Normalize to loading controls (PGK1, tubulin)

• Stress response analysis:

  • Subject yeast to various stressors (heat shock, oxidative stress, osmotic stress)

  • Compare YHR140W expression levels between control and stressed samples

  • Correlate with functional assays to determine significance

• Nutrient availability response:

  • Culture yeast in media with varying carbon or nitrogen sources

  • Assess YHR140W expression changes using quantitative Western blot

  • Develop a standardized protocol for consistent quantification

• Temporal expression dynamics:

  • Design time-course experiments following environmental changes

  • Collect samples at defined intervals

  • Create expression profile graphs with statistical analysis of replicates

How might open science initiatives impact YHR140W antibody research?

Based on information about the YCharOS initiative , several developments may enhance YHR140W antibody research:

• Comprehensive antibody validation:

  • Initiatives like YCharOS are working to characterize antibodies against the entire human proteome

  • Similar approaches could be extended to model organism proteins like YHR140W

  • Standardized validation across multiple techniques (Western blot, immunoprecipitation, immunofluorescence)

• Open access to validation data:

  • Centralized repositories similar to Zenodo and F1000 could house YHR140W antibody validation data

  • Searchable databases like Antibody Registry may include comprehensive validation metrics

  • This transparency would allow researchers to make more informed antibody selections

• Industry-academic partnerships:

  • Collaborative approaches between commercial suppliers and academic researchers

  • Joint development of improved antibodies based on performance data

  • Potential withdrawal or reformulation of poorly performing reagents

The established collaborative open science model demonstrated by YCharOS suggests significant potential returns on investment for the scientific community when applied to reagents like YHR140W antibodies .

What emerging technologies might enhance YHR140W antibody development?

Several emerging technologies could improve YHR140W antibody quality and applications:

• Renewable antibody sources:

  • Recombinant antibody production instead of animal-derived polyclonals

  • Development of YHR140W-specific nanobodies or single-chain variable fragments

  • These approaches would enhance reproducibility between batches

• Enhanced screening methods:

  • High-throughput epitope mapping to identify optimal binding sites

  • Next-generation sequencing of antibody repertoires to identify high-affinity binders

  • Machine learning approaches to predict epitope accessibility and antibody performance

• Alternative detection strategies:

  • Development of proximity ligation assays for enhanced sensitivity

  • Adaptation of CRISPR-based tagging systems to visualize endogenous YHR140W

  • Integration with mass spectrometry approaches for quantitative analysis

How can researchers adapt antibody-free methods to complement YHR140W antibody studies?

To address limitations inherent to antibody-based detection, researchers might consider these complementary approaches:

• CRISPR-based tagging:

  • Gene editing to introduce epitope tags (FLAG, HA, V5) into the endogenous YHR140W locus

  • Allows detection with highly validated tag-specific antibodies

  • Enables visualization of protein dynamics in living cells

• Fluorescent protein fusions:

  • Generation of YHR140W-GFP/mCherry fusion constructs

  • Live-cell imaging of protein localization and dynamics

  • Quantitative analysis of expression levels through fluorescence measurement

• Mass spectrometry approaches:

  • Targeted proteomics using selected reaction monitoring (SRM) or parallel reaction monitoring (PRM)

  • Label-free quantification of YHR140W across experimental conditions

  • Identification of post-translational modifications and interaction partners

• RNA-based expression analysis:

  • qRT-PCR or RNA-seq to quantify YHR140W transcript levels

  • Correlation between transcript and protein levels

  • Analysis of expression regulation through promoter studies

What are the key considerations for researchers selecting YHR140W antibodies?

When selecting YHR140W antibodies, researchers should prioritize:

• Comprehensive validation data:

  • Evidence of specificity through knockout controls

  • Performance metrics in multiple applications

  • Reproducibility across batches

• Application-specific validation:

  • Confirmation that the antibody works specifically in your intended application

  • Technical support availability for protocol optimization

  • Published literature using the same antibody for similar applications

• Experimental controls:

  • Plan for both positive and negative controls

  • Include appropriate loading controls for quantitative work

  • Design peptide competition assays when necessary

The lessons from YCharOS and similar initiatives demonstrate that even commercially available antibodies require careful validation in specific experimental contexts .

How should researchers document and report YHR140W antibody use in publications?

Based on best practices in antibody research, publications should include:

• Complete antibody information:

  • Supplier name and location

  • Catalog number and lot number

  • Antibody type (polyclonal/monoclonal) and host species

  • RRID (Research Resource Identifier) if available

• Validation evidence:

  • Description of controls used to verify specificity

  • References to previous validation studies

  • Data demonstrating appropriate performance in the specific application

• Detailed methods:

  • Complete protocols including blocking, dilutions, and incubation times

  • Buffer compositions and washing procedures

  • Image acquisition parameters for microscopy or blot imaging

  • Quantification methods if applicable